4 Analysts Have This to Say About Freeline Therapeutics
Portfolio Pulse from Benzinga Insights
Freeline Therapeutics (NASDAQ:FRLN) has received two bullish and two indifferent ratings from analysts in the last quarter. The average 12-month price target for the company has increased by 362.5% from $2.00 to $9.25, with a high of $15.00 and a low of $3.00.
August 16, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Freeline Therapeutics has received mixed analyst ratings, with an increased 12-month price target.
The mixed analyst ratings indicate uncertainty about the company's performance. However, the significant increase in the 12-month price target suggests that analysts see potential for the stock's price to rise.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100